Orgovyx 120 mg film-coated tablets
Sponsors
Ziekenhuis Aan De Stroom, UZ Leuven, Friedrich-Schiller-Universitaet Jena, Central Finland Hospital District Central Finland Hospital Nova, IRCCS Istituto Nazionale Tumori Fondazione Pascale
Conditions
Oligorecurrent hormone-sensitive prostate cancer patientsProstate CancerProstate cancerprostate cancer
Phase 2
Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
RecruitingCTIS2023-504704-28-00
Start: 2024-09-01Target: 310Updated: 2025-12-17
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
RecruitingCTIS2022-501551-90-00
Start: 2023-12-13Target: 583Updated: 2026-01-23
REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery
Not yet recruitingCTIS2025-521170-33-00
Target: 50Updated: 2025-07-17
Phase 3
Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
RecruitingCTIS2022-502373-42-00
Start: 2022-04-25Target: 873Updated: 2025-03-31
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)
Active, not recruitingCTIS2022-502634-52-00
Start: 2023-05-16Target: 280Updated: 2025-08-25